United Therapeutics Moves Toward the First Inhaled Antifibrotic for IPF

Insilico Medicine's rentosertib (INS018_055) has entered Phase III development for IPF

Skye Bioscience and Redx Pharma announced plans to form fibrosis-focused Fibrx Therapeutics

Global interest continues to surge following Eli Lilly's $630 million licensing deal with OliX Pharmaceuticals for the MASH/obesity cross-indication asset OLX702A

Yuhan Develops Anti-Fibrosis Drug Candidate, Wins U.S. Patent

Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets